We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+57.31%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$253M
AUM Growth
+$105M
(+72%)
Cap. Flow
+$69.1M
Cap. Flow
% of AUM
27.37%
Top 10 Holdings %
Top 10 Hldgs %
50.9%
Holding
95
New
29
Increased
11
Reduced
6
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$8.24M |
| 2 |
Biohaven
BHVN
|
+$6.93M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$5.72M |
| 4 |
Larimar Therapeutics
LRMR
|
+$5.42M |
| 5 |
HELP
Cybin Inc
HELP
|
+$5.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
+$9.75M |
| 2 |
ATXS
Astria Therapeutics
ATXS
|
+$7.32M |
| 3 |
Immunovant
IMVT
|
+$3.37M |
| 4 |
Oric Pharmaceuticals
ORIC
|
+$3.22M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$2.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.9% |
| 2 | Consumer Discretionary | 1.37% |
| 3 | Industrials | 0.06% |
| 4 | Communication Services | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Insmed
INSM
$28.6B
| $3.26M | 1.29% |
120,000
| – | – |
|
27
The RealReal
REAL
$1.6B
| $3.13M | 1.24% |
+800,000
| New | +$1.91M |
|
|
ALPN
28
DELISTED
Alpine Immune Sciences Inc
ALPN
| $3.09M | 1.22% |
77,848
-875
| -1% | -$25.8K |
|
|
BOLD
29
Boundless Bio
BOLD
$63.6M
| $2.85M | 1.13% |
+200,000
| New | +$2.85M |
|
30
Aquestive Therapeutics
AQST
$507M
| $2.83M | 1.12% |
+665,000
| New | +$2.21M |
|
31
Rhythm Pharmaceuticals
RYTM
$7.97B
| $2.48M | 0.98% |
57,271
+50,786
| +783% | +$2.22M |
|
32
Milestone Pharmaceuticals
MIST
$149M
| $2.17M | 0.86% |
+1,212,882
| New | +$1.97M |
|
|
ATXS
33
DELISTED
Astria Therapeutics
ATXS
| $2.01M | 0.79% |
142,532
-587,468
| -80% | -$7.32M |
|
34
Zevra Therapeutics
ZVRA
$685M
| $1.98M | 0.78% |
+341,461
| New | +$2.1M |
|
|
RAPT
35
CALL
DELISTED
RAPT Therapeutics
RAPT
| $1.8M | 0.71% |
+25,000
| New | +$3.48M |
|
|
MRNS
36
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.6M | 0.63% |
176,840
-23,160
| -12% | -$225K |
|
37
BioVie
BIVI
$7.69M
| $1.59M | 0.63% |
+30,126
| New | +$3.09M |
|
|
TRML
38
DELISTED
Tourmaline Bio
TRML
| $1.5M | 0.59% |
+65,442
| New | +$2.31M |
|
39
Veru
VERU
$37.7M
| $1.48M | 0.59% |
211,173
+11,173
| +6% | +$59.5K |
|
40
CALL
Geron
GERN
$1B
| $1.32M | 0.52% |
+400,000
| New | +$896K |
|
41
Karyopharm Therapeutics
KPTI
$44.6M
| $1.12M | 0.44% |
49,333
| – | – |
|
|
FATBW
42
DELISTED
FAT Brands Inc. Warrant
FATBW
| $974K | 0.39% |
200,000
| – | – |
|
|
SPRB
43
Spruce Biosciences
SPRB
$126M
| $904K | 0.36% |
+15,333
| New | +$3.9M |
|
44
Perspective Therapeutics
CATX
$340M
| $637K | 0.25% |
+53,566
| New | +$457K |
|
|
EVOK
45
DELISTED
Evoke Pharma
EVOK
| $442K | 0.18% |
+60,412
| New | +$513K |
|
|
PMNT
46
DELISTED
PERFECT MOMENT LTD
PMNT
| $330K | 0.13% |
+92,208
| New | +$409K |
|
47
Rocket Pharmaceuticals Warrant
RCKTW
$288K
| $219K | 0.09% |
+731,561
| New | +$232K |
|
48
NexGel Inc Warrant
NXGLW
| $162K | 0.06% |
225,000
| – | – |
|
|
MOB
49
Mobilicom Ltd
MOB
$73.7M
| $161K | 0.06% |
+135,292
| New | +$194K |
|
|
GRI
50
GRI Bio
GRI
$2.74M
| $143K | 0.06% |
+30
| New | +$256K |
|
Similar funds
TA
SIM
VEPM
VI
BCM
VAM
SCM
CAS
Altium Capital Management's Q1 2024 Portfolio in Review
As of Q1 2024, Altium Capital Management held 95 positions worth $253M, up 72% from $147M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Altium Capital Management deployed $69.1M of net new capital in Q1 2024, opening 29 new positions and adding to 11 existing holdings. Its largest new stake was Avadel Pharmaceuticals: 553,057 shares worth $9.34M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier, followed by Consumer Discretionary and Industrials.
On the sell side, the largest reduction was Astria Therapeutics, an estimated $7.32M trimmed.
- Altium Capital Management's largest Q1 2024 buy was Avadel Pharmaceuticals: 553,057 shares worth $9.34M.
- Altium Capital Management added most to Vera Therapeutics in Q1 2024, an estimated $3.39M increase.
- Altium Capital Management's biggest Q1 2024 reduction was Astria Therapeutics, cutting an estimated $7.32M.
- Altium Capital Management fully exited Alpha Architect 1-3 Month Box ETF in Q1 2024, selling an estimated $9.75M.
- Altium Capital Management's ten largest holdings make up 51% of its $253M portfolio in Q1 2024.
- Altium Capital Management opened 29 new positions and closed 23 in Q1 2024.
- Altium Capital Management's portfolio value rose 72% quarter-over-quarter to $253M.
Based on Altium Capital Management's 13F filing for Q1 2024, filed 15 May 2024.